Strategic Partnerships Circio is actively entering collaborations to advance circVec circular RNA technology and AAV vector platforms, presenting clear cross-selling opportunities with gene therapy developers, cell therapy engineers, and non-viral vector firms seeking safer, scalable RNA-based solutions.

Cardiovascular Focus Recent and ongoing collaborations target heart disease and cardiovascular applications, suggesting a primary market focus for sales outreach to cardio-biotech companies, contract research organizations, and pharma groups pursuing gene therapies for cardiac conditions.

Clinical Progress As a clinical-stage biotechnology with ongoing trials for RAS vaccines and plans for ONCOS-102 phase 2 financing, Circio may need CROs, manufacturing partners, and regulatory consultants to support IND-enabling studies and clinical development infrastructure.

Financing runway A NOK300m funding round, extending runway to 2030, indicates substantial investor activity and appetite for partnerships around platform expansion, making Circio a potential co-development or co-commercialization candidate for late-stage collaborations.

Global Collaboration Strategic alignments with international entities (Karolinska Institutet, Tcelltech, GenAssist, Aavigen) demonstrate openness to cross-border R&D and technology transfer, signaling sales opportunities with global biotechs and service providers seeking access to Circio’s circVec and vector platforms.